One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Aiming Targeted Drug Development at Rare Pediatric Malignancies.
doi : 10.1200/JCO-25-00009
Volume 43(10) pgs. 1173-1270,e2-e30 April 1, 2025
Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials: An Ethical Imperative.
doi : 10.1200/JCO-24-02021
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
doi : 10.1200/JCO.24.00848
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823).
doi : 10.1200/JCO-24-01854
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
doi : 10.1200/JCO-24-01549
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
doi : 10.1200/JCO.24.00953
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
doi : 10.1200/JCO-24-01519
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.
doi : 10.1200/JCO-24-01875
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.
doi : 10.1200/JCO.24.01118
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
doi : 10.1200/JCO-24-01349
Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1[alpha] Activation.
doi : 10.1200/JCO-24-02305
Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1[alpha] Activation.
doi : 10.1200/JCO-24-02610
Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1[alpha] Activation.
doi : 10.1200/JCO-24-02684
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
doi : 10.1200/JCO-25-00353
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
doi : 10.1200/JCO-24-02785
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
doi : 10.1200/JCO-24-02786
